# EDGAR Filing Document

**Accession Number:** 0001746473
**File Stem:** 0001746473-26-000054
**Filing Date:** 2026-4
**Character Count:** 10839
**Document Hash:** 19af5d548f6b44349abae1686e4b2db5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001746473-26-000054.hdr.sgml**: 20260417

**ACCESSION NUMBER**: 0001746473-26-000054

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260417

**FILED AS OF DATE**: 20260417

**DATE AS OF CHANGE**: 20260417

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Cummings Keith Lamont
- **CENTRAL INDEX KEY:** 0001809204

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39303
- **FILM NUMBER:** 26872208

**MAIL ADDRESS:**
- **STREET 1:** C/O PLIANT THERAPEUTICS, INC.
- **STREET 2:** 331 OYSTER POINT BOULEVARD
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PLIANT THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001746473
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474272481
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 331 OYSTER POINT BOULEVARD
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-481-6770

**MAIL ADDRESS:**
- **STREET 1:** 331 OYSTER POINT BOULEVARD
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Cummings Keith Lamont<br><sub>(Last) (First) (Middle)</sub><br>C/O PLIANT THERAPEUTICS, INC.<br>331 OYSTER POINT BOULEVARD<br><sub>(Street)</sub><br>SOUTH SAN FRANCISCO, CA 94080<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-17 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Financial Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>PLIANT THERAPEUTICS, INC. [ PLRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $2.08 | 2026-04-17 |  | D<sup>(1)</sup> |  |  | 76047 | <sup>(2)</sup> | 2029-01-24<sup>(3)</sup> | Common Stock | 76047 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | 1.33<sup>(4)(5)</sup> | 2026-04-17 |  | A<sup>(1)</sup> |  | 76047 |  | <sup>(2)</sup> | 2029-01-24<sup>(3)</sup> | Common Stock | 76047 | $0 | 76047 | D |  |
| Stock Option (Right to Buy) | $6.22 | 2026-04-17 |  | D<sup>(1)</sup> |  |  | 18198 | <sup>(2)</sup> | 2030-03-31<sup>(6)</sup> | Common Stock | 18198 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | 1.33<sup>(4)(5)</sup> | 2026-04-17 |  | A<sup>(1)</sup> |  | 18198 |  | <sup>(2)</sup> | 2030-03-31<sup>(6)</sup> | Common Stock | 18198 | $0 | 18198 | D |  |
| Stock Option (Right to Buy) | $26.50 | 2026-04-17 |  | D<sup>(1)</sup> |  |  | 74250 | <sup>(2)</sup> | 2031-01-23<sup>(7)</sup> | Common Stock | 74250 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | 1.33<sup>(4)(5)</sup> | 2026-04-17 |  | A<sup>(1)</sup> |  | 74250 |  | <sup>(2)</sup> | 2031-01-23<sup>(7)</sup> | Common Stock | 74250 | $0 | 74250 | D |  |
| Stock Option (Right to Buy) | $11.86 | 2026-04-17 |  | D<sup>(1)</sup> |  |  | 124000 | <sup>(2)</sup> | 2032-01-26<sup>(8)</sup> | Common Stock | 124000 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | 1.33<sup>(4)(5)</sup> | 2026-04-17 |  | A<sup>(1)</sup> |  | 124000 |  | <sup>(2)</sup> | 2032-01-26<sup>(8)</sup> | Common Stock | 124000 | $0 | 124000 | D |  |
| Stock Option (Right to Buy) | $34.65 | 2026-04-17 |  | D<sup>(1)</sup> |  |  | 76200 | <sup>(2)</sup> | 2033-01-25<sup>(9)</sup> | Common Stock | 76200 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | 1.33<sup>(4)(5)</sup> | 2026-04-17 |  | A<sup>(1)</sup> |  | 76200 |  | <sup>(2)</sup> | 2033-01-25<sup>(9)</sup> | Common Stock | 76200 | $0 | 76200 | D |  |
| Stock Option (Right to Buy) | $17.44 | 2026-04-17 |  | D<sup>(1)</sup> |  |  | 110500 | <sup>(2)</sup> | 2034-01-23 | Common Stock | 110500 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | 1.33<sup>(4)(5)</sup> | 2026-04-17 |  | A<sup>(1)</sup> |  | 110500 |  | <sup>(2)</sup> | 2034-01-23 | Common Stock | 110500 | $0 | 110500 | D |  |
| Stock Option (Right to Buy) | $11.14 | 2026-04-17 |  | D<sup>(1)</sup> |  |  | 113300 | <sup>(2)</sup> | 2035-01-23 | Common Stock | 113300 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | 1.33<sup>(4)(5)</sup> | 2026-04-17 |  | A<sup>(1)</sup> |  | 113300 |  | <sup>(2)</sup> | 2035-01-23 | Common Stock | 113300 | $0 | 113300 | D |  |

---

### Footnotes:

(1) On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged.

(2) The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date.

(3) The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029.

(4) The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan).

(5) The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan).

(6) The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030.

(7) The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031.

(8) The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032.

(9) The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033.

**Signature:** /s/ Jennifer Woo, attorney-in-fact  
**Date:** 2026-04-17

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**